Financials Summit Therapeutics Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 19:00:01 10/02/2026 GMT			5-day change	1st Jan Change
15.34 ^USD	+2.44%		+5.04%	-12.38%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Fiscal Period: December	2020	2023	2024	2025	2026	2027
Net sales ¹	14.54	-	-	57.43	1.774	64.5
Change	-	-	-	-	-96.91%	3,534.89%
EBITDA ¹	-	-	-108.4	-368.3	-404.6	-463.6
Change	-	-	-	-239.72%	-9.85%	-14.57%
EBIT ¹	-38.35	-	-178.8	-732.3	-601.1	-589
Change	-	-	-	-309.59%	17.91%	2.01%
Interest Paid	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-	-	-175.1	-815.1	-667.9	-632.9
Change	-	-	-	-365.59%	18.06%	5.23%
Net income ¹	-	-486.2	-175.1	-796.9	-595.3	-553.7
Change	-	-	64%	-355.21%	25.3%	6.98%
Announcement Date	17/03/21	20/02/24	24/02/25	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	3.279	5.641	4.455	0.9759	-	-	-	-	-	-	-	57.43	-	-	0.8218	3.072	-	-	-
Change	-	72.05%	-21.02%	-78.1%	-	-	-	-	-	-	-	-	-	-	-	273.84%	-	-	-
EBITDA ¹	-	-	-	-	-	-47.06	-44.67	-34.51	-50.29	-	-174.4	126.9	-96.7	-102.3	-	-	-	-	-
Change	-	-	-	-	-	-	5.07%	22.76%	-45.74%	-	-	172.75%	-176.21%	-5.78%	-	-	-	-	-
EBIT ¹	-8.331	-16.92	-17.12	-14.53	-33.85	-46.69	-44.92	-51.89	-50.31	-423.9	-174.9	-86.78	-172	-178.8	-201.2	-203.7	-	-	-
Change	-	-103.13%	-1.14%	15.13%	-133.03%	-37.93%	3.8%	-15.53%	3.06%	-742.66%	58.75%	50.37%	-98.23%	-3.92%	-12.55%	-1.24%	-	-	-
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-	-	-	-	-	-	-	-48.41	-47.34	-421.9	-173.1	-175	-190	-196.9	-200.7	-203.1	-	-	-
Change	-	-	-	-	-	-	-	-	2.21%	-791.15%	58.98%	-1.14%	-8.54%	-3.66%	-1.88%	-1.21%	-	-	-
Net income ¹	-	-	-	-	-	-	-	-48.41	-47.34	-421.9	-173.1	-157.3	-190	-197	-200.7	-203.1	-	-	-
Change	-	-	-	-	-	-	-	-	2.21%	-791.15%	58.98%	9.09%	-20.77%	-3.66%	-1.88%	-1.2%	-	-	-
Announcement Date	17/03/21	17/05/21	11/08/21	15/11/21	01/05/24	06/08/24	30/10/24	24/02/25	01/05/25	11/08/25	20/10/25	-	-	-	-	-	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2020	2023	2024	2025	2026	2027
Net Debt ¹	-	-	-	-338	-129	-62.4
Change	-	-	-	-	61.83%	51.63%
Announcement Date	17/03/21	20/02/24	24/02/25	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2024	2025	2026	2027
CAPEX ¹	0.11	0.4171	0.544	4.682
Change	-	279.11%	30.44%	760.71%
Free Cash Flow (FCF) ¹	-112.6	-557.3	-490.7	-428.1
Change	-	-395.06%	11.95%	12.77%
Announcement Date	24/02/25	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-	-641.34%	-22,802.64%	-718.74%
EBIT Margin (%)	-263.7%	-	-	-	-	-1,275%	-33,877.39%	-913.27%
EBT Margin (%)	-	-	-	-	-	-1,419.18%	-37,638.74%	-981.28%
Net margin (%)	-	-	-	-	-	-1,387.56%	-33,546.87%	-858.48%
FCF margin (%)	-	-	-	-	-	-970.38%	-27,655.11%	-663.68%
FCF / Net Income (%)	-	-	-	-	64.31%	69.93%	82.44%	77.31%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-	-	-	-	-94.9%	-13.68%	-74.06%	-205.97%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	0.73%	30.66%	7.26%
CAPEX / EBITDA (%)	-	-	-	-	-0.1%	-0.11%	-0.13%	-1.01%
CAPEX / FCF (%)	-	-	-	-	-0.1%	-0.07%	-0.11%	-1.09%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	0.593	0.19	0.015
Change	-	-	-	-	-	-	-67.96%	-92.11%
EPS ¹	-	-	-	-0.7828	-0.2452	-0.9686	-0.7371	-0.7009
Change	-	-	-	-	68.67%	-294.96%	23.9%	4.92%
Nbr of stocks (in thousands)	-	-	-	700,843	737,448	771,150	771,150	771,150
Announcement Date	-	-	-	20/02/24	24/02/25	-	-	-